癌バイオマーカーの世界市場:インサイト、市場機会、市場シェア、市場予測

◆英語タイトル:Global Cancer Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022
◆商品コード:OCCAM61109
◆発行会社(リサーチ会社):Occams Research
◆発行日:2016年9月
◆ページ数:140
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD3,900 ⇒換算¥429,000見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD6,910 ⇒換算¥760,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はOccams Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Occams Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、癌バイオマーカーの世界市場について調査・分析し、市場インサイト、市場機会、市場シェア、市場規模予測などを含め、以下の構成でお届けいたします。

・癌バイオマーカーの世界市場:イントロダクション
・癌バイオマーカーの世界市場:市場概観
・癌バイオマーカーの世界市場:市場動向(促進要因、阻害要因、市場機会)
・癌バイオマーカーの世界市場:セグメント別市場分析
・癌バイオマーカーの世界市場:癌種類別分析/市場規模
・癌バイオマーカーの世界市場:バイオマーカー種類別分析/市場規模
・癌バイオマーカーの世界市場:技術別分析/市場規模
・癌バイオマーカーの世界市場:用途別分析/市場規模
・癌バイオマーカーの世界市場:主要地域別市場分析
・癌バイオマーカーの世界市場:関連企業分析
【レポートの概要】

The global cancer biomarkers market is anticipated to reach around $17 billion by 2022, with an estimated CAGR of 12.6% from 2016 to 2022. The market growth is driven by factors such as increasing prevalence of cancer, various technological developments in omics technologies; increased demand for personalized medicines especially in cancer therapies, rising number of clinical trials in developed as well as developing countries; favorable government research funding for cancer research; and rising R&D expenditures by pharmaceutical companies. However, poorly suited regulatory and reimbursement systems of biomarker tests and huge capital investments for biomarker discovery and development are restricting the growth of this market.
In this report, the global cancer biomarkers market is segmented on the basis of type of cancer biomarker, tumor type, profiling technologies, applications, and geographical region. Based on type, the market is again divided into protein biomarkers, genetic biomarkers, and other type of biomarkers for example viral cell biomarkers, and carbohydrate biomarkers. Based upon type of tumor, the market is divided into breast cancer type biomarkers, lung cancer, colorectal cancer, prostate cancer, cervical cancer biomarkers and other type of cancers which comprise of gastrointestinal stromal tumors, lung, ovarian, bladder, kidney, melanoma, and leukemia. Based on profiling technologies, the market is divided into omics technologies, imaging technologies, cytogenetics, immunoassays, and bioinformatics. Based upon applications, the market is again segmented into diagnostics, drug discovery and development, prognostics, risk assessment, and others which consist of surrogate endpoints, recurrence, personalized medicine, and therapeutics. On the basis of global region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America and Middle East and Africa).

In 2015, North America accounted for the largest share in the global cancer biomarkers market, followed by European region, Asia-Pacific, and RoW. This huge growth in the North American market is majorly due to cumulative government support for discovery and development of biomarkers, increasing demand for personalized medicine, early adoption of various technologically advanced omics for the biomarker discovery, and the growing application of biomarkers for drug discovery and development by pharmaceutical companies in the region. However, the Asia-Pacific market is expected to witness high growth in the forecast period, owing to rising prevalence of cancer, increasing government support, expansion by major market players, and increasing use of biomarker tests for diagnosis in this region. The diagnostics segment in this market is accounted for a major share of the cancer biomarkers market, which is followed by drug discovery and development. This is mainly attributed to the increasing prevalence of cancer; increasing demand for advanced diagnostics tests, growing awareness, acceptance of diagnostics tests, and advancement in technologies, and the need for early-stage cancer diagnosis.

Prominent players which are included in this global cancer biomarkers market report are Abbott Laboratories (U.S.), Affymetrix Inc. (U.S.), Roche Diagnostics Ltd. (Switzerland), Illumina, Inc. (U.S.), Qiagen NV (Netherlands),Hologic Inc. (U.S.), Agilent Technologies (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.).

【レポートの目次】

1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW
2.1. MARKET DEFINITION AND SCOPE
2.2. KEY FINDINGS
2.3. PARAMETRIC ANALYSIS
2.4. KEY MARKET INSIGHTS
2.4.1. TOP EMERGING COUNTRIES
2.4.2. TOP REVENUE GENERATING SEGMENTS
2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
2.4.4. TOP GEOGRAPHY
2.5. COMPETITIVE LANDSCAPE
2.5.1. MARKET SHARE ANALYSIS
2.5.2. TOP WINNING STRATEGIES
2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
2.6. PORTER’S FIVE FORCE MODEL
2.6.1. THREAT OF NEW ENTRANTS
2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
2.6.3. BARGAINING POWER OF BUYER
2.6.4. BARGAINING POWER OF SUPPLIER
2.6.5. INTENSITY OF COMPETITIVE RIVALRY
2.7. KEY BUYING CRITERIA
2.8. STRATEGIC RECOMMENDATION
2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. RISING CANCER PREVALENCE
3.1.2. ENHANCED ACCURACY AND SPEED OF DIAGNOSIS
3.1.3. INCREASING RESEARCH ON CANCER BIOMARKERS
3.1.4. FDA SUPPORT FOR BIOMARKER DEVELOPMENT
3.2. MARKET RESTRAINTS
3.2.1. POOR REIMBURSEMENT SYSTEMS
3.2.2. HIGH CAPITAL INVESTMENT AND LOW BENEFIT-COST RATIO
3.2.3. TECHNICAL ISSUES OF SAMPLE COLLECTION AND STORAGE
3.3. MARKET OPPORTUNITIES
3.3.1. PERSONALIZED MEDICINE
3.3.2. COMPANION DIAGNOSTICS
3.3.3. EMERGING ECONOMIES
3.4. MARKET CHALLENGES
3.4.1. PROVING CLINICAL VALIDITY AND UTILITY OF BIOMARKER-BASED TESTS LEADING TO THEIR INSUFFICIENT ACCEPTANCE
3.5. PARENT MARKET
3.6. ALTERNATIVE MARKET

4. MARKET SEGMENTATION
4.1. BY TUMOR TYPE
4.1.1. GLOBAL CANCER BIOMARKER MARKET BY BREAST CANCER 2014-2022 ($ MILLION)
4.1.2. GLOBAL CANCER BIOMARKER MARKET BY LUNG CANCER 2014-2022 ($ MILLION)
4.1.3. GLOBAL CANCER BIOMARKER MARKET BY COLORECTAL CANCER 2014-2022 ($ MILLION)
4.1.4. GLOBAL CANCER BIOMARKER MARKET BY PROSTATE CANCER 2014-2022 ($ MILLION)
4.1.5. GLOBAL CANCER BIOMARKER MARKET BY CERVICAL CANCER 2014-2022 ($ MILLION)
4.1.6. GLOBAL CANCER BIOMARKER MARKET BY OTHERS CANCERS 2014-2022 ($ MILLION)
4.2. BY TYPE
4.2.1. GLOBAL CANCER BIOMARKER MARKET BY GLOBAL CANCER BIOMARKER PROTEIN BIOMARKERS 2014-2022 ($ MILLION)
4.2.2. GLOBAL CANCER BIOMARKER MARKET BY GENETIC BIOMARKERS 2014-2022 ($ MILLION)
4.2.3. GLOBAL CANCER BIOMARKER MARKET BY OTHERS CANCER BIOMARKERS 2014-2022 ($ MILLION)
4.3. BY PROFILING TECHNOLOGIES
4.3.1. GLOBAL CANCER BIOMARKER MARKET BY IMMUNOASSAYS 2014-2022 ($ MILLION)
4.3.2. GLOBAL CANCER BIOMARKER MARKET BY OMICS TECHNOLOGIES 2014-2022 ($ MILLION)
4.3.2.1. GLOBAL CANCER BIOMARKER MARKET BY GENOMICS 2014-2022 ($ MILLION)
4.3.2.2. GLOBAL CANCER BIOMARKER MARKET BY PROTEOMICS 2014-2022 ($ MILLION)
4.3.2.3. GLOBAL CANCER BIOMARKER MARKET BY OTHERS OMICS TECHNOLOGIES 2014-2022 ($ MILLION)
4.3.3. GLOBAL CANCER BIOMARKER MARKET BY CYTOGENETICS 2014-2022 ($ MILLION)
4.3.4. GLOBAL CANCER BIOMARKER MARKET BY IMAGING TECHNOLOGIES 2014-2022 ($ MILLION)
4.3.5. GLOBAL CANCER BIOMARKER MARKET BY BIOINFORMATICS 2014-2022 ($ MILLION)
4.4. BY APPLICATION
4.4.1. GLOBAL CANCER BIOMARKER MARKET BY DIAGNOSTICS 2014-2022 ($ MILLION)
4.4.2. GLOBAL CANCER BIOMARKER MARKET BYDRUG DISCOVERY AND DEVELOPMENT2014-2022 ($ MILLION)
4.4.3. GLOBAL CANCER BIOMARKER MARKET BY PROGNOSTICS 2014-2022 ($ MILLION)
4.4.4. GLOBAL CANCER BIOMARKER MARKET BY RISK ASSESSMENT 2014-2022 ($ MILLION)
4.4.5. GLOBAL CANCER BIOMARKER MARKET BY OTHERS 2014-2022 ($ MILLION)

5. GEOGRAPHICAL ANALYSIS
5.1. NORTH AMERICA GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.1.1. UNITED STATES (U.S.) GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.1.2. CANADA GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.2. EUROPE GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.2.1. UNITED KINGDOM (UK) GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.2.2. FRANCE GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.2.3. GERMANY GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.2.4. SPAIN GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.2.5. ITALY GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.2.6. ROE GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)

5.3. ASIA PACIFIC GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.3.1. INDIA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.3.2. CHINA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.3.3. JAPAN CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.3.4. KOREA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.3.5. AUSTRALIA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.3.6. ROAPAC CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.4. REST OF THE WORLD GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.4.1. LATIN AMERICA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.4.2. MENA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
5.4.3. AFRICA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)

6. COMPANY PROFILES
1. ABBOTT LABORATORIES
2. AFFYMETRIX, INC.
3. AGENDIA BV
4. AGILENT TECHNOLOGIES, INC.
5. AMBRILIABIOPHARMA
6. ASTELLAS PHARMA US INC.
7. AUREON LABORATORIES INC.
8. BECKMAN COULTER
9. BECTON DICKINSON AND COMPANY
10. BIOMODA INC.
11. CLARIENT, INC.
12. DIADEXUS INC.
13. ILLUMINA, INC.
14. QIAGEN N.V.
15. ROCHE DIAGNOSTICS LTD.

LIST OF TABLES
1. GLOBAL CANCER BIOMARKER MARKET BY BREAST CANCER 2014-2022 ($ MILLION)
2. GLOBAL CANCER BIOMARKER MARKET BY LUNG CANCER 2014-2022 ($ MILLION)
3. GLOBAL CANCER BIOMARKER MARKET BY COLORECTAL CANCER 2014-2022 ($ MILLION)
4. GLOBAL CANCER BIOMARKER MARKET BY PROSTATE CANCER 2014-2022 ($ MILLION)
5. GLOBAL CANCER BIOMARKER MARKET BY CERVICAL CANCER 2014-2022 ($ MILLION)
6. GLOBAL CANCER BIOMARKER MARKET BY OTHERS CANCERS 2014-2022 ($ MILLION)
7. GLOBAL CANCER BIOMARKER MARKET BY GLOBAL CANCER BIOMARKER PROTEIN BIOMARKERS 2014-2022 ($ MILLION)
8. GLOBAL CANCER BIOMARKER MARKET BY GENETIC BIOMARKERS 2014-2022 ($ MILLION)
9. GLOBAL CANCER BIOMARKER MARKET BY OTHERS CANCER BIOMARKERS 2014-2022 ($ MILLION)
10. GLOBAL CANCER BIOMARKER MARKET BY IMMUNOASSAYS 2014-2022 ($ MILLION)
11. GLOBAL CANCER BIOMARKER MARKET BY OMICS TECHNOLOGIES 2014-2022 ($ MILLION)
12. GLOBAL CANCER BIOMARKER MARKET BY GENOMICS 2014-2022 ($ MILLION)
13. GLOBAL CANCER BIOMARKER MARKET BY PROTEOMICS 2014-2022 ($ MILLION)
14. GLOBAL CANCER BIOMARKER MARKET BY OTHERS OMICS TECHNOLOGIES 2014-2022 ($ MILLION)
15. GLOBAL CANCER BIOMARKER MARKET BY CYTOGENETICS 2014-2022 ($ MILLION)
16. GLOBAL CANCER BIOMARKER MARKET BY IMAGING TECHNOLOGIES 2014-2022 ($ MILLION)
17. GLOBAL CANCER BIOMARKER MARKET BY BIOINFORMATICS 2014-2022 ($ MILLION)
18. GLOBAL CANCER BIOMARKER MARKET BY DIAGNOSTICS 2014-2022 ($ MILLION)
19. GLOBAL CANCER BIOMARKER MARKET BY DRUG DISCOVERY AND DEVELOPMENT 2014-2022 ($ MILLION)
20. GLOBAL CANCER BIOMARKER MARKET BY PROGNOSTICS 2014-2022 ($ MILLION)
21. GLOBAL CANCER BIOMARKER MARKET BY RISK ASSESSMENT 2014-2022 ($ MILLION)
22. GLOBAL CANCER BIOMARKER MARKET BY OTHERS 2014-2022 ($ MILLION)
23. NORTH AMERICA GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
24. EUROPE GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
25. ASIA PACIFIC GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
26. REST OF THE WORLD GLOBAL CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)

LIST OF FIGURES
1. GLOBAL CANCER BIOMARKER MARKET BY BREAST CANCER 2014-2022 ($ MILLION)
2. GLOBAL CANCER BIOMARKER MARKET BY LUNG CANCER 2014-2022 ($ MILLION)
3. GLOBAL CANCER BIOMARKER MARKET BY COLORECTAL CANCER 2014-2022 ($ MILLION)
4. GLOBAL CANCER BIOMARKER MARKET BY PROSTATE CANCER 2014-2022 ($ MILLION)
5. GLOBAL CANCER BIOMARKER MARKET BY CERVICAL CANCER 2014-2022 ($ MILLION)
6. GLOBAL CANCER BIOMARKER MARKET BY OTHERS CANCERS 2014-2022 ($ MILLION)
7. GLOBAL CANCER BIOMARKER MARKET BY GLOBAL CANCER BIOMARKER PROTEIN BIOMARKERS 2014-2022 ($ MILLION)
8. GLOBAL CANCER BIOMARKER MARKET BY GENETIC BIOMARKERS 2014-2022 ($ MILLION)
9. GLOBAL CANCER BIOMARKER MARKET BY OTHERS CANCER BIOMARKERS 2014-2022 ($ MILLION)
10. GLOBAL CANCER BIOMARKER MARKET BY IMMUNOASSAYS 2014-2022 ($ MILLION)
11. GLOBAL CANCER BIOMARKER MARKET BY OMICS TECHNOLOGIES 2014-2022 ($ MILLION)
12. GLOBAL CANCER BIOMARKER MARKET BY GENOMICS 2014-2022 ($ MILLION)
13. GLOBAL CANCER BIOMARKER MARKET BY PROTEOMICS 2014-2022 ($ MILLION)
14. GLOBAL CANCER BIOMARKER MARKET BY OTHERS OMICS TECHNOLOGIES 2014-2022 ($ MILLION)
15. GLOBAL CANCER BIOMARKER MARKET BY CYTOGENETICS 2014-2022 ($ MILLION)
16. GLOBAL CANCER BIOMARKER MARKET BY IMAGING TECHNOLOGIES 2014-2022 ($ MILLION)
17. GLOBAL CANCER BIOMARKER MARKET BY BIOINFORMATICS 2014-2022 ($ MILLION)
18. GLOBAL CANCER BIOMARKER MARKET BY DIAGNOSTICS 2014-2022 ($ MILLION)
19. GLOBAL CANCER BIOMARKER MARKET BY DRUG DISCOVERY AND DEVELOPMENT 2014-2022 ($ MILLION)
20. GLOBAL CANCER BIOMARKER MARKET BY PROGNOSTICS 2014-2022 ($ MILLION)
21. GLOBAL CANCER BIOMARKER MARKET BY RISK ASSESSMENT 2014-2022 ($ MILLION)
22. GLOBAL CANCER BIOMARKER MARKET BY OTHERS 2014-2022 ($ MILLION)
23. UNITED STATES (U.S.) CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
24. CANADA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
25. UNITED KINGDOM (UK) CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
26. FRANCE CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
27. GERMANY CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
28. SPAIN CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
29. ITALY CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
30. ROE CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
31. INDIA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
32. CHINA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
33. JAPAN CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
34. KOREA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
35. AUSTRALIA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
36. ROAPAC CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
37. LATIN AMERICA CANCER BIOMARKER MARKET, 2014-2022, ($MILLIONS)
38. MENA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)
39. AFRICA CANCER BIOMARKER MARKET 2014-2022 ($ MILLION)



【レポートのキーワード】

癌バイオマーカー

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 癌バイオマーカーの世界市場:インサイト、市場機会、市場シェア、市場予測(Global Cancer Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆